News

03Jun

Statement Regarding Recent Media Coverage

Basildon, UK, 3 June 2016 – Atnahs Pharma is providing the following statement in relation to recent media coverage. Atnahs Pharma (“Atnahs”) is a UK registered limited company founded in 2013. The company makes and sells medicines both into the UK and internationally. Atnahs acquires the rights to make medicines from large pharmaceutical companies at…

Read more

11May

Atnahs Acquires Naproxen Suspension in the US

Basildon, UK, May 11 2016 – Atnahs Pharma US Limited (“Atnahs”) is pleased to announce that the Food and Drug Administration (“FDA”) has granted supplement approval to the manufacturing site transfer of Naproxen Suspension in the US. This has triggered the second and final US$ 2 million payment in a total transaction of US$4.25 million.

Read more

31Mar

Atnahs Acquires Majority Stake in Pharmanovia A/S in Denmark

Basildon, UK, March 31 2016 – Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of a majority stake in Pharmanovia A/S (“Pharmanovia”) in Denmark. Pharmanovia is a speciality pharma business with a portfolio and accompanying pipeline of nice products.

Read more

31Jan

Atnahs Acquires Naproxen Suspension in the US

Basildon, UK, January 31 2016 – Atnahs Pharma US Limited (“Atnahs”) is pleased to announce the acquisition of Naproxen Suspension from Pediapharm Inc. in a total transaction of US$4.25 million. The product is currently awaiting Food and Drug Administration (“FDA”) Supplement Approval regarding the manufacturing site transfer.

Read more

02Apr

Atnahs Acquires Naprosyn®, Anaprox® and Toradol®

Basildon, UK, April 2015 – Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of Naprosyn®, Anaprox® and Toradol® from F.Hoffmann-La Roche Limited, effective from 31st March 2015. Naprosyn® and Anaprox® are oral treatments for rheumatoid arthritis, osteoarthrosis (degenerative arthritis), acute gout and acute musculoskeletal disorders. Toradol® is an injectable and oral treatment…

Read more

14Mar

Atnahs Acquires Dipentum®

Basildon, UK, March 2014 – Atnahs Pharma UK Limited (“Atnahs”) is delighted to announce that, as part of its on-going strategy of developing the business we have completed the acquisition of Dipentum® from UCB Pharma Limited, effective from 1st January 2014. Dipentum® is an oral treatment for mild active ulcerative colitis and the maintenance of…

Read more